Ligand Pharmaceuticals Financial Statements
Ligand Pharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Ligand Pharmaceuticals Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 27.3 | 12.9 | 141.0 |
| Gross Profit ($ mil.) | -- | -- | 118.3 |
| Operating Income ($ mil.) | (97.3) | (52.7) | (163.7) |
| Total Net Income ($ mil.) | (98.1) | 281.7 | (31.7) |
| Diluted EPS (Net Income) | (1.03) | 2.87 | (0.39) |
Ligand Pharmaceuticals Quarterly Statements
| Quarter Ending Sep 09 | Quarter Ending Jun 09 | Quarter Ending Mar 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 7.9 | 7.6 | 9.5 |
| Gross Profit ($ mil.) | (7.3) | -- | -- |
| Operating Income ($ mil.) | -- | (4.4) | (7.3) |
| Total Net Income ($ mil.) | 1.8 | (1.7) | (5.1) |
| Diluted EPS (Net Income) | 0.02 | (0.01) | (0.05) |
Ligand Pharmaceuticals Stock Quote & Chart
11/06/09 16:00:02 EST •
NASDAQ •
2.00
•
 +0.0900
•
+4.7120 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Ligand Pharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 6.02 | 16.45 | 7.01 |
| Price/Earnings Ratio | (2.21) | 384.62 | 25.51 |
| Price/Book Ratio | (23.81) | 3.53 | 6.74 |
| Price/Cash Flow Ratio | (7.36) | 80.00 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Ligand Pharmaceuticals Financial Ratios
Ligand Pharmaceuticals Competitive Intelligence
| Eli Lilly | Merck | Protalex | |
|---|---|---|---|
| Annual Sales ($ mil.) | 20,378.0 | 18,502.0 | 0.0 |
| Employees | 40,500 | 51,000 | -- |
| Market Cap ($ mil.) | 39,560.8 | 46,142.1 | 1.4 |
Competitive Landscape
